T.Man Pharmaceutical Public Company (TMAN) Fair Value & Analysis
Healthcare · TH · Market cap 4.6B THB
Fair value as of: Jul 20, 2026
From 24 valuation models · updated 21 days ago
Share price −0.9% over the past month.
A solid business, screening 65% undervalued on our models.
What matters now
- The model range is unusually wide (9.98 THB to 29.91 THB). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (22 months)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
22‑month range 9.47 THB – 16.22 THB · fair‑value band 9.98 THB – 29.91 THB · the 10.80 THB price screens below the 17.80 THB fair value. Dashed = 300-day average. As of Jul 20, 2026.
Analysis
T.Man Pharmaceutical Public Company (TMAN) currently trades at 10.80 THB, while our model-based Fair Value estimate is 17.80 THB, implying the stock looks roughly 64.8% undervalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, T.Man Pharmaceutical Public Company generated revenue of 2.5B THB at a net margin of 20.7%. Revenue grew 25.9% year over year. It earns a return on equity of 26.9%. Net debt stands at 476M THB. Fundamentals as of Jul 20, 2026
Our scenario range runs from 9.98 THB (bear case) to 29.91 THB (bull case); at 10.80 THB, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 18% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 65%, TMAN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (23.00 THB) versus Asset-Based (3.55 THB). Highest evidence: Growth DCF (80).
Notify me when TMAN reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 56 · Market factors (momentum, volatility) 44
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties' Brand, and Trading Products.
Full company description
T.Man Pharmaceutical Public Company Limited manufactures and sells pharmaceuticals and health care products in Thailand. The company operates through three segments: Manufactured Products Under Own Brand, Manufactured Products Under Third Parties' Brand, and Trading Products. It offers antibacterial, central nervous system, corticosteroid, chronic diseases, gastrointestinal, respiratory, and musculoskeletal drugs, as well as medical devices, vaginal suppositories, dermatological, mouth, and throat products. The company also provides herbal and traditional medicines, dietary supplements, vitamins and minerals, skin care and aesthetics, whey protein, and mommy and kid products, as well as cosmetics, modern medicines, mossi guard, nevtral, propolis, and vita-c products. In addition, it offers products under various brand names, such as Iyara, Propoliz, POLAR, and Fibermate. The company also exports its products. Further, the company offers original equipment manufacturing services. Additionally, it offers medicines in the form of tablets, capsules, powders, liquids, and semisolids. The company also exports its products. T.Man Pharmaceutical Public Company Limited was founded in 1991 and is based in Bangkok, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
T.Man Pharmaceutical Public Company reported revenue of 2.5B THB in FY2025 versus 2.0B THB in FY2022, a compound +7.5%/yr. Reported net income was 523M THB in FY2025, compounding +3.4%/yr from FY2022.
Watch TMAN: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.19 | ¥25.94 | -51% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹7,316 | ₹1,943 | -73% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,763 | ₹1,329 | -72% |
| PharmaEssentia Corporation 6446 | 1,285 TWD | 221.01 TWD | -83% |
| Cipla Limited CIPLA | ₹1,439 | ₹1,001 | -30% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,151 | ₹703.32 | -39% |
| Lupin Limited LUPIN | ₹2,443 | ₹2,477 | +1% |
| Mankind Pharma Limited MANKIND | ₹2,484 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,211 | ₹874.79 | -28% |
Compare T.Man Pharmaceutical Public Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is T.Man Pharmaceutical Public Company (TMAN) overvalued or undervalued?
What is the fair value of TMAN?
What is the quality score of TMAN?
What is the revenue of T.Man Pharmaceutical Public Company (TMAN)?
What is the net profit margin of TMAN?
Does T.Man Pharmaceutical Public Company pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track T.Man Pharmaceutical Public Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.